The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Daniela E. Matei

Melvin and Bren Simon Cancer Center

Indiana University

Bloomington

Indiana 46202

USA

[email]@iupui.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Melvin and Bren Simon Cancer Center, Indiana University, Bloomington, Indiana 46202, USA. 2012
  • Corresponding Author: Daniela Matei, Indiana University Simon Cancer Center, 535 Barnhill Drive, RT 473. 2012
  • Indiana University School of Medicine, Division of Hematology-Oncology, RT-457, 535 Barnhill Dr, USA. 2011
  • Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA. 2010
  • Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive RT-473, Indianapolis, IN 46202, USA. 2006 - 2010
  • Department of Medicine, Indiana University Melvin and Bren Simon Cancer Center and Walther Oncology Center, Indiana University School of Medicine, Indianapolis, USA. 2004 - 2007

References

  1. Epigenetic resensitization to platinum in ovarian cancer. Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W.A., Huang, T., Nephew, K.P. Cancer Res. (2012) [Pubmed]
  2. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Shao, M., Hollar, S., Chambliss, D., Schmitt, J., Emerson, R., Chelladurai, B., Perkins, S., Ivan, M., Matei, D. Mol. Cancer Ther. (2012) [Pubmed]
  3. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Matei, D., Sill, M.W., Lankes, H.A., DeGeest, K., Bristow, R.E., Mutch, D., Yamada, S.D., Cohn, D., Calvert, V., Farley, J., Petricoin, E.F., Birrer, M.J. J. Clin. Oncol. (2011) [Pubmed]
  4. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Matei, D.E., Nephew, K.P. Gynecol. Oncol. (2010) [Pubmed]
  5. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. Matei, D., Miller, A.M., Monahan, P., Gershenson, D., Zhao, Q., Cella, D., Champion, V.L., Williams, S.D. J. Clin. Oncol. (2009) [Pubmed]
  6. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Matei, D., Schilder, J., Sutton, G., Perkins, S., Breen, T., Quon, C., Sidor, C. Gynecol. Oncol. (2009) [Pubmed]
  7. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Matei, D., Emerson, R.E., Schilder, J., Menning, N., Baldridge, L.A., Johnson, C.S., Breen, T., McClean, J., Stephens, D., Whalen, C., Sutton, G. Cancer (2008) [Pubmed]
  8. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Satpathy, M., Cao, L., Pincheira, R., Emerson, R., Bigsby, R., Nakshatri, H., Matei, D. Cancer Res. (2007) [Pubmed]
  9. PDGF BB induces VEGF secretion in ovarian cancer. Matei, D., Kelich, S., Cao, L., Menning, N., Emerson, R.E., Rao, J., Jeng, M.H., Sledge, G.W. Cancer Biol. Ther. (2007) [Pubmed]
  10. Novel agents in ovarian cancer. Matei, D. Expert. Opin. Investig. Drugs (2007) [Pubmed]
  11. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. Matei, D., Satpathy, M., Cao, L., Lai, Y.C., Nakshatri, H., Donner, D.B. J. Biol. Chem. (2007) [Pubmed]
  12. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Matei, D., Emerson, R.E., Lai, Y.C., Baldridge, L.A., Rao, J., Yiannoutsos, C., Donner, D.D. Oncogene (2006) [Pubmed]
  13. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Matei, D., Chang, D.D., Jeng, M.H. Clin. Cancer Res. (2004) [Pubmed]
 
WikiGenes - Universities